Recent Updates
Recently added Catalysts

Limb-Girdle Muscular Dystrophy: one US-listed biotech with a clinical-stage programme

Rare Genetic & MetabolicUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$2.4Buniverse median $1.20B
Allocated capital$809M$2.4B competing
Phase 3 or filed10 mid, 0 early
Pure plays0this indication only
Capital rank161/299crowding rank 172

Limb-Girdle Muscular Dystrophy is uncontested. Sarepta Therapeutics (SRPT) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with SRP-9003 in phase 3.

There is no public comparable to price it against. SRPT spreads its $2.4B market cap across 3 indications, so $809M of it is allocated here.

The one programme here is in late-stage development, but it carries no dated catalyst in the next 12 months.

$809M of allocated capital sits in Limb-Girdle Muscular Dystrophy, ranking it 161st of 299 indications by the money committed to it.

Companies developing drugs for Limb-Girdle Muscular Dystrophy 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
SRPTSarepta TherapeuticsSRP-9003Phase 33$2.4BNo3No dated event

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Limb-Girdle Muscular Dystrophy counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Limb-Girdle Muscular Dystrophy has one competitor and a median of $2.4B.

Rare Genetic & Metabolic

Rare Genetic & Metabolic holds $103B of the map's capital, 15.3% of the total, spread across 32 indications and 48 companies. 10 of those indications have more than one company competing.

See every Rare Genetic & Metabolic indication on the map

Related indications in Rare Genetic & Metabolic

Mucopolysaccharidosis Type IIIA1 company · $729M · median $3.6BUncontestedLate-onset Pompe Disease1 company · $729M · median $3.6BUncontestedSanfilippo Syndrome (MPS IIIB)2 companies · $654M · median $815MOrphan cornerErythropoietic Protoporphyria1 company · $609M · median $3.0BUncontestedAntithrombin III Deficiency1 company · $1.0B · median $2.1BUncontestedVon Willebrand Disease1 company · $1.0B · median $2.1BUncontestedCongenital FVII Deficiency1 company · $1.0B · median $2.1BUncontestedMECP2 Duplication Syndrome1 company · $1.1B · median $9.7BUncontested

Limb-Girdle Muscular Dystrophy pipeline questions

Which biotech companies are developing drugs for Limb-Girdle Muscular Dystrophy?

Sarepta Therapeutics (SRPT, SRP-9003, Phase 3). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Limb-Girdle Muscular Dystrophy.

How advanced is the Limb-Girdle Muscular Dystrophy pipeline?

Of the 1 clinical-stage programme in Limb-Girdle Muscular Dystrophy, 1 is in Phase 3 or filed, 0 are in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Limb-Girdle Muscular Dystrophy?

No. SRPT is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Limb-Girdle Muscular Dystrophy, which is why the indication is classified as uncontested.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map